Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Operating Expenses (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Operating Expenses for 15 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 3.22% year-over-year to $1.2 million, compared with a TTM value of $4.1 million through Sep 2025, down 66.04%, and an annual FY2024 reading of $4.8 million, down 85.93% over the prior year.
  • Operating Expenses was $1.2 million for Q3 2025 at Alaunos Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $22.7 million in Q3 2021 and bottomed at $759000.0 in Q4 2024.
  • Average Operating Expenses over 5 years is $8.3 million, with a median of $8.5 million recorded in 2022.
  • The sharpest move saw Operating Expenses increased 21.68% in 2021, then crashed 90.45% in 2024.
  • Year by year, Operating Expenses stood at $11.1 million in 2021, then fell by 22.79% to $8.5 million in 2022, then dropped by 6.82% to $8.0 million in 2023, then plummeted by 90.45% to $759000.0 in 2024, then surged by 56.39% to $1.2 million in 2025.
  • Business Quant data shows Operating Expenses for TCRT at $1.2 million in Q3 2025, $1.0 million in Q2 2025, and $1.1 million in Q1 2025.